Morgan Stanley
ANVS icon

Morgan Stanley’s Annovis Bio ANVS Stock Holding History

Morgan Stanley’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$634 Sell
341
-5,392
-94% -$10.5K ﹤0.01% 7593
2026
Q1 		$12.8K Sell
5,733
-4,168
-42% -$11.4K ﹤0.01% 6877
2025
Q4 		$34.3K Buy
9,901
+2,512
+34% +$7.55K ﹤0.01% 6543
2025
Q3 		$15.3K Sell
7,389
-4,805
-39% -$12K ﹤0.01% 6769
2025
Q2 		$26.5K Buy
12,194
+2,005
+20% +$3.96K ﹤0.01% 6561
2025
Q1 		$15.3K Buy
10,189
+8,889
+684% +$27.2K ﹤0.01% 6657
2024
Q4 		$6.54K Sell
1,300
-50
-4% -$362 ﹤0.01% 6935
2024
Q3 		$10.9K Sell
1,350
-4,148
-75% -$38.9K ﹤0.01% 6695
2024
Q2 		$31.7K Sell
5,498
-1,658
-23% -$13.4K ﹤0.01% 6320
2024
Q1 		$85.2K Buy
7,156
+5,722
+399% +$62.4K ﹤0.01% 6053
2023
Q4 		$26.8K Hold
1,434
– – ﹤0.01% 6358
2023
Q3 		$13.6K Buy
1,434
+22
+2% +$272 ﹤0.01% 6609
2023
Q2 		$20.2K Sell
1,412
-289
-17% -$4.09K ﹤0.01% 6569
2023
Q1 		$26.2K Sell
1,701
-27,955
-94% -$451K ﹤0.01% 6529
2022
Q4 		$398K Sell
29,656
-11,631
-28% -$145K ﹤0.01% 5355
2022
Q3 		$566K Sell
41,287
-14,851
-26% -$195K ﹤0.01% 5208
2022
Q2 		$636K Sell
56,138
-53,920
-49% -$589K ﹤0.01% 5294
2022
Q1 		$1.47M Sell
110,058
-44,923
-29% -$649K ﹤0.01% 4731
2021
Q4 		$2.72M Buy
154,981
+117,015
+308% +$3.02M ﹤0.01% 4326
2021
Q3 		$1.21M Buy
37,966
+7,896
+26% +$454K ﹤0.01% 4922
2021
Q2 		$2.57M Buy
+30,070
New +$1.39M ﹤0.01% 4442
2021
Q1 		– Sell
-14,286
Closed -$108K – 7479
2020
Q4 		$108K Hold
14,286
– – ﹤0.01% 5876
2020
Q3 		$69K Buy
+14,286
New +$76.5K ﹤0.01% 5588

Other funds holding ANVS

EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Morgan Stanley's ANVS Position: Q2 2026 in Review

Morgan Stanley reduced its Annovis Bio (ANVS) stake by 94% in Q2 2026, selling an estimated $10.5K and leaving 341 shares worth $634. The position accounts for ﹤0.01% of the portfolio, ranked #7593.

Morgan Stanley first reported a position in ANVS in Q3 2020 and has held it in 23 quarters since. The position peaked at $2.72M in Q4 2021. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

  • Morgan Stanley held 341 shares of Annovis Bio worth $634 as of Q2 2026.
  • Morgan Stanley sold 5,392 Annovis Bio shares in Q2 2026, an estimated $10.5K.
  • Annovis Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7593 holding.
  • Morgan Stanley first reported a position in Annovis Bio in Q3 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Annovis Bio position peaked at $2.72M in Q4 2021.
  • 61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.